Search Result

Results for "

3CLPro Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Apoptosis (3) Bacterial (4) Cathepsin (1) Cytochrome P450 (4) Endogenous Metabolite (5) Flavivirus (1) Fungal (2) HBV (1) HCV (8) HCV Protease (7) HIV (10) HIV Protease (10) Isotope-Labeled Compounds (9) NO Synthase (1) P-glycoprotein (4) PKC (1) Proteasome (1) Reference Standards (8) SARS-CoV (68) Ser/Thr Protease (1) Thrombopoietin Receptor (1) Virus Protease (11) Xanthine Oxidase (1)
By Research Areas:	Cancer (10) Infection (68) Inflammation/Immunology (4) Metabolic Disease (3) Neurological Disease (1)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-162674

MERS-CoV-IN-2	SARS-CoV	Infection
MERS-CoV-IN-2 (compound 3c) is a MERS-CoV 3CLpro inhibitor (IC₅₀=17nM). MERS-CoV-IN-2 inhibits the activity of the *3CLpro* enzyme by binding to the active site of the enzyme, specifically the S4 subsite, thereby exhibiting antiviral activity against SARS-CoV-2 and MERS-CoV .

HY-W760546

SARS-CoV-2 3CLpro-IN-15	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). SARS-CoV-2 3CLpro-IN-15 inhibits viral replication and transcription and plays a key role in the discovery of anti-COVID-19 lead compounds .

HY-N12384

(25S)-Antcin B	SARS-CoV	Infection
Antcin-B is a potent inhibitor of *3CLPro* with high affinity. Antcin-B can be used in study SARS-CoV-2 .

HY-169410

SARS-CoV-2 3CLpro-IN-29	SARS-CoV Virus Protease	Infection
3CLPro-IN-3 (Compound A36) is an inhibitor for SARS-CoV-2 3CLpro with IC₅₀ of 51.3 nM. 3CLPro-IN-3 exhibits antiviral activity against human coronavirus 229E, OC43 and mouse hepatitis virus MHV .

HY-155979

SARS-CoV-2 3CLpro-IN-16	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC₅₀: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro .

HY-147804

SARS-CoV-2 3CLpro-IN-3	SARS-CoV Bacterial Fungal	Infection
SARS-CoV-2 3CLpro-IN-3 (Compound 3d) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .

HY-170357

SARS-CoV-2 3CLpro-IN-28	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-28 (Compound 19) is an inhibitor for SARS-CoV-2 3CLpro with an IC₅₀ of 0.018 μM .

HY-173575

SARS-CoV-2 3CLpro-IN-31	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-31 (Compound 13c) is a potent SARS-CoV-2 3CL protease (3CLpro) inhibitor of with an IC₅₀ value of 37.33 nM. SARS-CoV-2 3CLpro-IN-31 blocks viral polyprotein cleavage and inhibits SARS-CoV-2 replication. SARS-CoV-2 3CLpro-IN-31 is promising for research of SARS-CoV-2 infection .

HY-147805

SARS-CoV-2 3CLpro-IN-4	SARS-CoV Bacterial Fungal	Infection
SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities .

HY-155980

SARS-CoV-2 3CLpro-IN-17	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.322 μM) .

HY-172906

SARS-CoV-2 3CLpro-IN-32	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-32 (compound B16) is a potent SARS-CoV-2 3CLpro inhibitor with an IC₅₀ of 0.109 μM. SARS-CoV-2 3CLpro-IN-32 also exhibits anti-coronavirus HCoV-OC43 activity with an EC₅₀ of 1.99 μM .

HY-161919

SARS-CoV-2 3CLpro-IN-25	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-25 (compound 56) inhibits the SARS-CoV-2 3CLpro with the IC50 of 70 nM and displays antiviral activity in cells with the EC50 of 3.1 μM .

HY-155981

SARS-CoV-2 3CLpro-IN-18	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.478 μM). SARS-CoV-2 3CLpro-IN-18 inhibits SARS-CoV-2 in Vero E6 cells (EC₅₀= 2.499 μM) with low cytotoxicity (CC₅₀ > 200 μM) .

HY-155187

SARS-CoV-2 3CLpro-IN-20	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.43 μM, K_i: ?0.33?μM) .

HY-151535

SARS-CoV-2 3CLpro-IN-5	SARS-CoV	Infection Inflammation/Immunology
SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CL ^pro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CL ^pro with an IC₅₀ value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-155540

SARS-CoV-2 3CLpro-IN-14	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally active SARS-CoV-2 3CLpro inhibitor. SARS-CoV-2 3CLpro-IN-14 shows significant anti-SARS-CoV-2 activity (EC₅₀ = 0.18 μM) and low cytotoxicity (CC₅₀ > 50 μM) in Vero E6 cells .

HY-168152

SARS-CoV-2 3CLpro-IN-26	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-26 (Compound (S,R)-4y) is an allosteric inhibitor for SARS-CoV-2 3CLpro with an IC₅₀ of 0.43 μM. SARS-CoV-2 3CLpro-IN-26 exhibits good cell permeability and is able to effectively cross the cell membrane, after co-incubation with Vero-E6 cells .

HY-146998

SARS-CoV-2 3CLpro-IN-2	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-2 (Compound 1) is a potent inhibitor of 3CL protease. SARS-CoV-2 3CLpro-IN-2 has the potential for the research of SARS-CoV-2 diseases .

HY-168430

SARS-CoV-2 3CLpro-IN-30	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-30 (compound 29) is a potent inhibitor of SARS-CoV-2 3CL protease (SARS-CoV-2 3CLpro), with the IC₅₀ and EC₅₀ of 0.04 and 0.3 μM .

HY-149264

SARS-CoV-2 3CLpro-IN-13	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-13 is a potent SARS-CoV-2 3CL protease inhibitor with an IC₅₀ value of 21 nM. SARS-CoV-2 3CLpro-IN-13 shows anti-coronavirus activity .

HY-157477

SARS-CoV-2 3CLpro-IN-22	SARS-CoV Cathepsin	Infection
SARS-CoV-2 3CLpro-IN-22 (Compound 17) is a cathepsin L (CTSL ) inhibitor with an IC₅₀ value of 32.5 nM. SARS-CoV-2 3CLpro-IN-22 can be used for the study of SARS-CoV-2 virus .

HY-152005

SARS-CoV-2 3CLpro-IN-6	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CL ^pro with an IC₅₀ value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19) .

HY-155186

SARS-CoV-2 3CLpro-IN-19	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC₅₀ values between 30-69 nM .

HY-144260

3CPLro-IN-1	SARS-CoV	Infection
3CPLro-IN-1 (compound A17) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC₅₀ of 5.65 μM. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .

HY-149535

Iscartrelvir WU-04	SARS-CoV	Infection
Iscartrelvir (WU-04) is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein. Iscartrelvir has high inhibitory effect on the 3CLpro protein of 6 SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Lambda and Omicron) and 2 coronaviruses (SARS-CoV and MERS-CoV) .

HY-144263

3CPLro-IN-2	SARS-CoV	Infection
3CPLro-IN-2 (compound C1) is a potent and orally active inhibitor of SARS-CoV-2 3CLpro with an IC₅₀ and K_i of 1.55 and 6.09 μM, respectively. 3-Chymotrypsin-like cysteine protease (3CLpro) is an indispensable protein in viral replication and represents an attractive agent target for fighting COVID-19 .

HY-168564

SARS-CoV-2 3CLpro-IN-27	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-27 (Compound 9H) is an inhibitor of SARS-CoV-2 3CL ^pro with an IC₅₀ value of 21 nM. SARS-CoV-2 3CLpro-IN-27 exhibits excellent anti-SARS-CoV-2 replicon activity, demonstrating an EC₅₀ value of 5 nM .

HY-138078

Lufotrelvir 1 Publications Verification PF-07304814	SARS-CoV	Infection
Lufotrelvir (PF-07304814), a phosphate proagent of PF-00835231, acts as a potent 3CLpro protease (Mpro) inhibitor with SARS-CoV-2 antiviral activity. Lufotrelvir binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174nM. Lufotrelvir is promising single antiviral agent and also can be used for the research of combination with other antivirals that target other critical stages of the coronavirus life cycle.

HY-W614623

(S)-ML188	Virus Protease SARS-CoV	Infection
(S)-ML188 is a SARS-CoV 3-chymotrypsin-like protease (3CLpro) inhibitor (IC₅₀: 1.5 μM). (S)-ML188 has antiviral activity with an EC₅₀ value of 12.9 μM against SARS-CoV. (S)-ML188 inhibits the activity of 3CLpro via non-covalent binding and can be used in the study of SARS-CoV .

HY-156007

SARS-CoV-2 3CLpro-IN-21	SARS-CoV Virus Protease	Infection
SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CL ^pro with an IC₅₀ of 0.03 μM. SARS-CoV-2 3CLpro-IN-21 also inhibits SARS-CoV-13CL ^pro with an IC₅₀ of 0.12μM .

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL ^pro. 3CL ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

HY-100721

GC376 sodium 5 Publications Verification	Virus Protease	Infection
GC376 sodium is a *3CLpro* inhibitor; inhibits the replication of viruses TGEV, FIPV and PTV with IC₅₀ values of 0.15, 0.2 and 0.15 μM, respectively.

HY-136259

ML188 5 Publications Verification	SARS-CoV Virus Protease	Infection
ML188, a first in class probe, is a selective non-covalent SARS-CoV *3CLpro* inhibitor with an IC₅₀ of 1.5 μM. Antiviral activity .

HY-175029

ALG-097558	SARS-CoV Virus Protease	Infection
ALG-097558 is an orally active *3CLpro* inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various SARS-CoV-2 variants as well as other human coronaviruses (HCoVs) such as SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC₅₀s of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].

HY-132886

SARS-CoV-2-IN-6	SARS-CoV	Infection
SARS-CoV-2-IN-6 is a SARS-CoV-2 3CLpro inhibitor that shows the most potent enzyme inhibitory IC₅₀ value of 73 nM.

HY-144747

Hydroxyethylamine	SARS-CoV	Infection
Hydroxyethylamine (Compd VII) is a SARS-CoV-2 3CLpro inhibitor with an IC₅₀ of ~10 μM in the spread assay. Hydroxyethylamine has potent antiviral activities .

HY-163912

JZD-07	SARS-CoV	Infection
JZD-07 is a potent SARS-CoV 3CLpro inhibitor. JZD-07 can be used in the study of SARS-CoV-2 infection .

HY-162236

SARS-CoV-2-IN-80	SARS-CoV	Infection
SARS-CoV-2-IN-80 (compound 13) is a potent SARS-CoV-2 3CLpro inhibitor with an IC₅₀ value of 0.964 µM .

HY-145277

SARS-CoV-2-IN-11	SARS-CoV	Infection
SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-145276

SARS-CoV-2-IN-10	SARS-CoV	Infection
SARS-CoV-2-IN-10 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC₅₀ and EC₅₀ of 0.13 and 1.03 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals .

HY-152009

SARS-CoV-2 3CLpro-IN-7	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC₅₀ value of 1.4 µM .

HY-150691

SARS 3CLpro-IN-1	SARS-CoV	Cancer
SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC₅₀ value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole .

HY-90001S

Ritonavir-d6 ABT 538-d₆; RTV-d₆	HIV Protease HIV SARS-CoV Apoptosis	Infection
Ritonavir-d₆ is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-N8306

Isojacareubin	Bacterial PKC Apoptosis SARS-CoV	Cancer
Isojacareubin can be isolated from Hypericum japonicum. Isojacareubin covalently inhibits SARS-CoV-2 3CLpro. Isojacareubin also has anti-helicobacter activity. Isojacareubin inhibits PKC, and suppresses hepatocellular carcinoma metastasis and induces apoptosis .

HY-137954

GRL-0496	SARS-CoV	Infection
GRL-0496 is a potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitor, with an IC₅₀ of 30 nM in both enzyme inhibitory and antiviral assays. GRL-0496 shows SARS-CoV antiviral activity, with an EC₅₀ of 6.9 μM .

HY-90001S1

Ritonavir-13C,d3 ABT 538-¹³C,d₃; RTV-¹³C,d₃	HIV Protease HIV SARS-CoV Apoptosis	Infection
Ritonavir- ¹³C,d₃ is the ¹³C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.

HY-17430S1

Amprenavir-d4-1 VX-478-d₄-1	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV	Infection Cancer
Amprenavir-d₄-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-17430S

Amprenavir-d4	Isotope-Labeled Compounds HIV HIV Protease SARS-CoV	Infection Cancer
Amprenavir-d₄ is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.09 μM .

HY-17430R

Amprenavir (Standard) VX-478 (Standard)	Reference Standards HIV HIV Protease SARS-CoV	Infection Cancer
Amprenavir (Standard) is the analytical standard of Amprenavir. This product is intended for research and analytical applications. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-W399297R

Isodeoxycholic acid (Standard) 7α,12α-Dihydroxycholanoic acid (Standard)	Endogenous Metabolite Reference Standards	Metabolic Disease
Amprenavir (Standard) is the analytical standard of Amprenavir. This product is intended for research and analytical applications. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

Cat. No.	Product Name	Type

HY-B0961

Merbromin Mercury dibromofluorescein disodium salt; ZP1	Dyes
Merbromin is a mixed inhibitor of the 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2, with an IC₅₀ of 2.7 μM. Merbromin effectively inhibits the replication of the Zika virus (ZIKV) and shows anti-ZIKV activity by inhibiting ZIKVpro. Merbromin can also be used as a topical disinfectant for cuts and scrapes, and it serves as a biological dye .

Cat. No.	Product Name	Type

HY-D0837R

Imidazole (Standard)

Glyoxaline (Standard); 1,3-Diaza-2,4-cyclopentadiene (Standard)

Cell Assay Reagents

Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8306

Isojacareubin	Flavonoids Flavones Source classification Guttiferae Plants Hypericum japonicum Thunb. ex Murray	Bacterial PKC Apoptosis SARS-CoV
Isojacareubin can be isolated from Hypericum japonicum. Isojacareubin covalently inhibits SARS-CoV-2 3CLpro. Isojacareubin also has anti-helicobacter activity. Isojacareubin inhibits PKC, and suppresses hepatocellular carcinoma metastasis and induces apoptosis .

HY-N12384

(25S)-Antcin B	Triterpenes Microorganisms Terpenoids Source classification	SARS-CoV
Antcin-B is a potent inhibitor of *3CLPro* with high affinity. Antcin-B can be used in study SARS-CoV-2 .

HY-W399297R

Isodeoxycholic acid (Standard) 7α,12α-Dihydroxycholanoic acid (Standard)	Source classification Endogenous metabolite Steroids	Endogenous Metabolite Reference Standards
Amprenavir (Standard) is the analytical standard of Amprenavir. This product is intended for research and analytical applications. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-17367AR

Atazanavir sulfate (Standard) BMS-232632 sulfate (Standard)	Alkaloids Source classification Pyridine Alkaloids Endogenous metabolite	Reference Standards HIV HIV Protease SARS-CoV Cytochrome P450 P-glycoprotein Endogenous Metabolite
Atazanavir (sulfate) (Standard) is the analytical standard of Atazanavir (sulfate). This product is intended for research and analytical applications. Atazanavir (BMS-232632) sulfate, a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir sulfate is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir sulfate is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 3.49 μM .

HY-N0063R

Punicalagin (Standard)	Punica granatum L. Source classification Phenols Polyphenols Punicaceae Plants	Reference Standards SARS-CoV HBV
Punicalagin (Standard) is the analytical standard of Punicalagin. This product is intended for research and analytical applications. Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CLpro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19 .

Cat. No.	Product Name	Chemical Structure

HY-90001S

Ritonavir-d6
Ritonavir-d₆ is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-15602S

Ledipasvir-d6
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.62 μM .

HY-90001S3

rel-Ritonavir-d6
rel-Ritonavir-d₆ (rel-ABT 538-d₆) is the deuterium labeled rel-Ritonavir. rel-Ritonavir is a relative configuration of Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to study of HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-17367S4

Atazanavir-d6

Atazanavir-d₆ is deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 3.49 μM .

HY-90001S1

Ritonavir-13C,d3
Ritonavir- ¹³C,d₃ is the ¹³C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.

HY-17430S1

Amprenavir-d4-1
Amprenavir-d₄-1 is deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.09 μM.

HY-17430S

Amprenavir-d4
Amprenavir-d₄ is the deuterium labeled Amprenavir. Amprenavir (VX-478) is a HIV protease inhibitor (Ki=0.6 nM) used to treat HIV infection. Amprenavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.09 μM .

HY-10237S

Boceprevir-d9
Boceprevir-d₉ is the deuterium labeled Boceprevir. Boceprevir (EBP 520) is a potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with a K_i of 14 nM in both enzyme assay and an EC₉₀ of 350 nM in cell-based replicon assay . Boceprevir inhibits SARS-CoV-2 3CLpro activity .

HY-17367S3

Atazanavir-d5

Atazanavir-d₅ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 3.49 μM .

HY-17367S2

Atazanavir-d9

Atazanavir-d₉ is the deuterium labeled Atazanavir. Atazanavir (BMS-232632), a highly selective HIV-1 protease inhibitor, is the first protease inhibitor approved for once-daily administration . Atazanavir (BMS-232632) is a substrate and inhibitor of CYP3A4, and an inhibitor and inducer of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 3.49 μM .

HY-10235S

Telaprevir-d4
Telaprevir-d₄ is the deuterium labeled Telaprevir. Telaprevir (VX-950) is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide . Telaprevir inhibits SARS-CoV-2 3CLpro activity .

HY-14588S1

Lopinavir-d8

Lopinavir-d₈ (ABT-378-d₈) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 14.2 μM .

Cat. No.	Product Name		Classification